Business Context and Reporting Period
This Form 8-K Current Report is filed by InspireMD, Inc. (Nasdaq: NSPR), a Delaware corporation, for the reporting period ending September 13, 2025. The filing primarily addresses Item 5.02 regarding the departure of a director and the appointment of a new director, along with associated compensatory arrangements.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to specific equity compensation grants:
- New Director Grant: Approximately $180,000 in aggregate value granted to Danny Lee Dearen Jr. (75% Restricted Stock, 25% Options).
- Resigning Director Grant: Approximately $120,000 in aggregate value granted to Thomas J. Kester (75% Common Stock, 25% Options), plus four additional quarters of board fees.
Material Changes
The filing reports significant changes to the Board of Directors:
- Resignation: Thomas J. Kester resigned as a Class III director, Compensation Committee member, and Audit Committee Chairman, effective September 16, 2025. The resignation was not due to any disagreement with the Company.
- Appointment: Danny Lee Dearen Jr. was appointed as a Class III director, Audit Committee Chairman, and Compensation Committee member, effective September 16, 2025. His term expires at the 2026 annual meeting.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, financial outlook, or discussion of general business risks. Management commentary is limited to the rationale for the board changes and the independence status of the new director. Mr. Dearen is deemed independent and an "audit committee financial expert." The filing notes that no material transactions involving Mr. Dearen have occurred since the beginning of the last fiscal year.
Investor Verification Checklist
- Verify the vesting schedule and exercise terms for the $180,000 equity grant to Mr. Dearen, specifically the acceleration clause if he is not reelected in 2026.
- Confirm the total cash compensation impact of the four additional quarters of fees paid to the departing director, Mr. Kester.
- Review the Company's 2021 Equity Compensation Plan to ensure sufficient shares remain available for these grants.
- Check subsequent filings for the formal election results of Mr. Dearen at the 2026 annual meeting of stockholders.